Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Author: , EminiEmilio A, GirgentiDouglas, GruberWilliam C, HalperinScott A, KellnerJames D, PattersonScott D, ScheifeleDavid W, ScottDaniel A, VanderkooiOtto G

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the compatibility, safety, and immunogenicity of PCV13 and PCV7, two pneumococcal conjugate vaccines. The study found that both vaccines were compatible with other vaccines and were safe and immunogenic.
Paper Details　
Original Abstract of the Article :
The global distribution of pneumococcal disease and emergence of nonvaccine pneumococcal serotypes prompted the development of a 13-valent pneumococcal conjugate vaccine (PCV13), with broader coverage than 7-valent PCV (PCV7). This study compared compatibility of PCV13 and PCV7 with concurrently adm...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0b013e318233049d

データ提供：米国国立医学図書館（NLM）

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine

The desert of infectious diseases is a constantly changing landscape, with new threats emerging all the time. This study evaluates the safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine (PCV13) in infants and toddlers, a crucial step in protecting vulnerable populations from pneumococcal infections.

The researchers conducted a study comparing the compatibility and safety of PCV13 with other routine pediatric vaccines. They also assessed its immunogenicity, evaluating its ability to elicit an immune response and protect against pneumococcal disease.

The study found that PCV13 was well-tolerated and safe when given concurrently with other routine pediatric vaccinations. It demonstrated robust immunogenicity, inducing a protective immune response against a wider range of pneumococcal serotypes than previous vaccines.

Expanding Protection Against Pneumococcal Disease

This research provides reassuring evidence of the safety and effectiveness of PCV13, a vital tool in protecting infants and toddlers from pneumococcal disease. The findings highlight the importance of vaccination programs in preventing this serious and potentially life-threatening illness.

Building a Strong Immunity in the Desert of Infection

Vaccination is an essential strategy for building a strong immune system and protecting ourselves from infectious diseases. This research underscores the importance of vaccination programs, especially for vulnerable populations like infants and toddlers. Like a camel navigating a treacherous desert, we must be equipped with the necessary tools and defenses to survive and thrive in a world full of potential threats.

Dr.Camel's Conclusion

This research is a testament to the power of vaccines in protecting our children. It demonstrates that PCV13, with its expanded coverage, offers a valuable weapon in the fight against pneumococcal disease. It's a reminder that by working together and leveraging the power of science, we can build a healthier and more resilient future for our children.

Date :
  1. Date Completed 2012-05-02
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

21960186

DOI: Digital Object Identifier

10.1097/INF.0b013e318233049d

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.